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Rochester, Minnesota
Objectives Our objective was to determine the prognostic value of plasma N-terminal pro-B-type natriuretic peptide
(NT-proBNP) for death and cardiovascular events among subjects without risk factors for heart failure (HF),
which we term healthy normal.
Background Previous studies report that plasma NT-proBNP has prognostic value for cardiovascular events in the general popula-
tion even in the absence of HF. It is unclear if NT-proBNP retains predictive value in healthy normal subjects.
Methods We identified a community-based cohort of 2,042 subjects in Olmsted County, Minnesota. Subjects with symp-
tomatic (stage C/D) HF were excluded. The remaining 1,991 subjects underwent echocardiography and NT-
proBNP measurement. We further defined healthy normal (n  703) and stage A/B HF (n  1,288) subgroups.
Healthy normal was defined as the absence of traditional clinical cardiovascular risk factors and echocardio-
graphic structural cardiac abnormalities. Subjects were followed for death, HF, cerebrovascular accident, and
myocardial infarction with median follow-up of 9.1, 8.7, 8.8, and 8.9 years, respectively.
Results NT-proBNP was not predictive of death or cardiovascular events in the healthy normal subgroup. Similar to previ-
ous reports, in stage A/B HF, plasma NT-proBNP values greater than age-/sex-specific 80th percentiles were as-
sociated with increased risk of death, HF, cerebrovascular accident, and myocardial infarction (p  0.001 for all)
even after adjustment for clinical risk factors and structural cardiac abnormalities.
Conclusions These findings do not support the use of NT-proBNP as a cardiovascular biomarker in healthy normal subjects and
have important implications for NT-proBNP–based strategies for early detection and primary prevention of cardiovas-
cular disease. (J Am Coll Cardiol 2010;55:2140–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.031t
w
s
s
c
a
c
e
m
c
the cardiac hormone B-type natriuretic peptide (BNP) has
roved useful in the diagnosis and prognosis of heart failure
HF) (1–3). In addition, we (4) and others (5–7) have
eported that plasma BNP, even in the absence of HF, has
ncremental prognostic value for future cardiovascular events
nd mortality beyond traditional cardiovascular risk factors
hen measured in large community-based samples. Impor-
rom the *Cardiorenal Research Laboratory, †Division of Cardiovascular Diseases,
nd the ‡Department of Biostatistics, Mayo Clinic and Foundation, Rochester,
innesota. This work was supported by grants from the National Institutes of Health
RO1 HL36634, R01-HL55502, and RO1 HL76611), the Stanley J. Sarnoff
ndowment for Cardiovascular Science, and the Mayo Division of Cardiology. Dr.
ataliotti was supported by the Doris Duke Charitable Foundation (CSDA 2006064)
nd by the M.I.U.R. Progetto Rientro dei Cervelli.p
Manuscript received July 15, 2009; revised manuscript received December 4, 2009,
ccepted January 11, 2010.antly, the plasma BNP values associated with increased risk
ere below those observed in HF. These previous studies
uggest, therefore, that there are mild although clinically
ignificant elevations in plasma BNP before the onset of
linically recognizable disease that may aid in identifying
t-risk subjects and help guide strategies to prevent adverse
ardiovascular outcomes.
See page 2148
In recent studies, we further reported the clinical and
chocardiographic phenotype of subjects with increased
ortality risk as predicted by plasma BNP in a large
ommunity-based cohort of 1,991 subjects without symp-
omatic HF (4). Specifically, there was a significantly higher
revalence of important cardiovascular clinical risk factors
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May 11, 2010:2140–7 NT-proBNP in Healthy Normal Subjectsnd echocardiographic structural and functional abnormal-
ties including hypertension, prior myocardial infarction,
ardiovascular drug use, left atrial enlargement, left ventric-
lar hypertrophy, and diastolic dysfunction among subjects
ith increased risk as predicted by plasma BNP. These
ndings suggested that subjects with increased mortality
isk defined by elevated plasma BNP values were dispropor-
ionately represented by those with stages A and B HF as
efined by the American College of Cardiology/American
eart Association (ACC/AHA) (8). Importantly, in-depth
linical examination and echocardiography permitted us to
dentify 703 subjects without clinical cardiovascular risk
actors or structural abnormalities who we define as healthy
ormal subjects. To date, the prognostic significance of
NP in predicting adverse cardiovascular outcomes has not
een determined in healthy normal subjects.
Based upon these previous findings, we hypothesized that
lasma BNP would not have prognostic significance for
ncreased mortality or adverse cardiovascular outcomes in
he healthy normal subgroup. This is a significant question
s healthy normal subjects represent 34% of the general
opulation (9) and, to date, the prognostic value of BNP to
redict increased mortality or cardiovascular morbidity in
ealthy normal subjects has not been addressed. Demon-
tration of a lack of prognostic value for BNP in healthy
ormal subjects is important because it may impact how we
creen for at-risk populations as well as design interven-
ional trials to decrease risk in such high-risk subjects.
To address this hypothesis, we utilized the comprehen-
ive clinical and echocardiographic data from the PAVD
Prevalence of Asymptomatic Ventricular Dysfunction)
tudy from Olmsted County, Minnesota, to identify a
ealthy normal cohort (n  703) and a stage A/B HF
ohort (1,288). Subjects with a history of symptomatic
F (stage C/D HF) were excluded. As amino-terminal
ro-BNP (NT-proBNP) was the most prognostic of the
NP assays in our previous studies (4), NT-proBNP was
sed for all analyses in the current study. Our results
stablish that NT-proBNP lacks prognostic value in the
bsence of underlying disease and/or alterations in car-
iac structure or function.
ethods
his study was approved by the Mayo Foundation and
lmsted Medical Center institutional review board.
tudy sample. Using the resources of the Rochester Epi-
emiology Project, a random sample of 2,042 Olmsted
ounty, Minnesota, residents ages 45 years was identi-
ed. The design and selection criteria of the PAVD study as
ell as the characteristics of the Olmsted County popula-
ion have been previously described (10–13). Of the 2,042
otal participants, 45 were excluded because of symptomatic
F (stages C and D HF by ACC/AHA guidelines) and,
onsistent with previous reports (4,5,7), 6 because of plasma
reatinine 2.0 mg/dl. The remaining 1,991 participants sere used for all analyses in this
tudy. Subjects were then charac-
erized as healthy normal (n 
03) if they had no clinical risk
actors or echocardiographic ab-
ormalities. Clinical risk factors
ere defined as documented cor-
nary artery disease (CAD), hy-
ertension, diabetes mellitus, prior
yocardial infarction, chronic
bstructive pulmonary disease,
istory of cardiovascular drug
se, peripheral vascular disease,
yperlipidemia, and absence of
ormal sinus rhythm. Echocar-
iographic abnormalities were left
entricular hypertrophy, left atrial
nlargement, regional wall motion abnormalities, valvular dys-
unction, ejection fraction 50%, and diastolic dysfunction.
he remaining subjects (n  1,288), with 1 or more clinical
isk factors or echocardiographic abnormalities, were classified
s stage A/B HF.
ain outcome measures. The Rochester Epidemiology
roject maintains a unified medical record including mor-
ality data. For mortality, participants were followed up
ntil death or May 2008, at which time they were censored.
his provided a mean 8.9 years of mortality follow-up, with
median (25th, 75th percentile) of 9.1 (8.5, 9.9) years. In
ddition to all-cause mortality, participants were monitored
ith respect to HF, myocardial infarction, stroke, and
ransient ischemic attack. Heart failure was defined as
nternational Classification of Diseases-Ninth Revision
ICD-9) code 402 or 428. Stroke and transient ischemic
ttack were grouped together under the term cerebrovascu-
ar accident (CVA) and included ICD-9 codes 430 to 438.
yocardial infarction was defined as ICD-9 code 410 or
12. For HF, CVA, and myocardial infarction participants
ere followed up until an event or May 1, 2008, at which
ime they were censored. This provided a median (25th,
5th percentile) of 8.7 (7.4, 9.8), 8.8 (6.3, 9.7), and 8.9 (7.3,
.8) years of follow-up for HF, CVA, and myocardial
nfarction, respectively. Because of the low number of events
n the healthy normal cohort, we assessed a combined end
oint of death, HF, CVA, and myocardial infarction with a
edian follow-up of 8.8 years. The combined end point was
ot assessed in the stage A/B HF cohort because of a
ufficient number of individual events.
oppler echocardiography. All echocardiograms were
erformed with the same echocardiographic instrument
HP-2500, Hewlett-Packard, Palo Alto, California) and
ere interpreted by a single echocardiologist blind to
T-proBNP values. Two-dimensional and color Doppler
maging were performed to screen for valvular stenosis and
egurgitation. In each subject, ejection fraction was mea-
ured and diastolic function categorized, as previously de-
Abbreviations
and Acronyms
BMI  body mass index
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
CVA  cerebrovascular
accident
HF  heart failure
IDI  integrated
discrimination improvement
NT-proBNP  N-terminal
pro-B-type natriuretic
peptidecribed (11,14). Left ventricular mass was calculated accord-
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NT-proBNP in Healthy Normal Subjects May 11, 2010:2140–7ng to the Devereux formula (15) and indexed to body
urface area. Presence of left ventricular hypertrophy was
efined on the basis of left ventricular mass index 130
/m2 for men and 100 g/m2 for women (16). Presence of
eft atrial enlargement was defined as left atrial volume index
33 ml/m2 in men and 30 ml/m2 in women (17).
nalysis of NT-proBNP. All 1,991 participants under-
ent NT-proBNP measurement with the Elecsys NT-
roBNP electrochemiluminescence immunoassay (Roche
iagnostics, Indianapolis, Indiana), as described previously
13,18). Interassay and intra-assay coefficients of variation
or NT-proBNP were 3.1% and 2.5%, respectively.
tatistical analysis. Descriptive statistics were used to
ummarize the data, continuous variables were expressed as
mean SD, and categorical variables by the percentage of
he category among the total group. The Wilcoxon rank-
um test was used to compare variables between the healthy
ormal cohort and stage A/B HF cohort. Survival and
vent-free rates after entry into the study were estimated
sing the Kaplan-Meier method. The association of out-
omes with clinical and echocardiographic variables and
T-proBNP levels was assessed using Cox proportional
azards regression.
As both sex and age significantly impact NT-proBNP
lasma values (13,19), we used cut points corresponding to
ge- and sex-adjusted 80th percentile values for NT-
roBNP (Fig. 1) in all analyses. The age- and sex-adjusted
0th percentile cut point values were obtained from the total
tudy sample (n  1,991), excluding subjects with stages C
nd D HF or creatinine2.0 mg/dl. Hazard ratios and 95%
onfidence intervals were calculated from unadjusted
nalyses, after adjustment for age, sex, and body mass
ndex (BMI) as well as from multivariable models with
raditional cardiovascular risk factors (age, sex, BMI,
Figure 1 Age- and Sex-Specific 80th Percentile Values
for Plasma NT-proBNP
Age- and sex-specific 80th percentile values for plasma N-terminal pro–B-type
natriuretic peptide (NT-proBNP) in the total study sample excluding subjects
with stages C and D heart failure or creatinine 2.0 (n  1,991). Solid line 
female; dashed line  male.Ciabetes mellitus, hypertension, serum total cholesterol,
AD, and serum creatinine) and finally from multivari-
ble models with both traditional cardiovascular risk
actors and echocardiographic abnormalities (ejection
raction 50%, diastolic dysfunction, valvular dysfunc-
ion, left ventricular hypertrophy, left atrial enlargement,
nd wall motion abnormalities).
The discriminative value of the NT-proBNP biomarker
or each outcome beyond known risk factors was evaluated
sing the integrated discrimination improvement (IDI)
pproach, as proposed by Pencina et al. (20,21). The IDI is
he difference in discriminative ability between 2 models
ccording to their predicted event probabilities. For in-
tance, in comparing 1 mortality model to another, an
aseline Characteristics of the Healthyormal and St ge A/B HF SubgroupsTable 1 B seline Charact ristics of the HealthyNormal and Stage A/B HF Subgroups
Healthy Normal
(n  703)
Stage A/B HF
(n  1,288)
Age, yrs 56 7* 65 10
Female, n (%) 370 (53) 667 (53)
BMI 28 4* 29 5
Systolic BP, mm Hg 124 17* 138 22
Diastolic BP, mm Hg 72 9* 75 10
Serum cholesterol, mg/dl
Total 208 35* 201 36
HDL 47 14† 46 15
Serum Cr, mg/dl 1.0 0.2* 1.1 0.2
LA volume index, ml/m2 21 5* 27 11
LV mass index, g/m2 88 14* 101 23
Ejection fraction, % 64 4 63 7
ata are presented as mean  1 SD. *p  0.001 compared to stage A/B heart failure (HF)
ubgroup. †p  0.031 compared to stage A/B HF subgroup.
BMI  body mass index; BP  blood pressure; Cr  creatinine; HDL  high-density lipoprotein;
A  left atria; LV  left ventricle.
revalence of Clinical and Echocardiographichar cteristics i the Stage A/B Heart Failure SubgroupTable 2 Prevalence of Clini l and Ec ocardiographicCharacteristics in the Stage A/B Heart Failure Subgroup
Prevalence (%) in the Stage A/B HF Subgroup
(n  1,288)
Coronary artery disease 16
Hypertension 42
Diabetes mellitus 11
Angina 10
Unstable angina 6
Prior myocardial infarction 6
Atrial fibrillation/flutter 6
Cardiomyopathy 1
COPD 6
Cardiovascular drug 54
Ejection fraction 50% 8
Valvular disease 6
Wall motion abnormality 6
Diastolic dysfunction 47
Left ventricular hypertrophy 18
Left atrial enlargement 24OPD  chronic obstructive pulmonary disease; other abbreviations as in Table 1.
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May 11, 2010:2140–7 NT-proBNP in Healthy Normal Subjectsncreased probability of death among subjects who died and
decreased probability of death among subjects who sur-
ived implies better predictive ability, whereas the opposite
mplies worse predictive ability. These 2 changes are
ummed (improvement always considered positive), and the
tandard error is calculated based on the sum of squares of
he standard errors for each mean change. Based on these
stimates, a 1-sample t test was used to test for a significant
DI. A 2-sided p value of 0.05 was deemed statistically
ignificant. The ability to classify risk was further assessed
ith the use of the c-statistic (22). The statistical software
ackage SAS version 8.2 (SAS Institute, Cary, North
arolina) was used for all analyses.
esults
tudy sample characterization. Baseline characteristics of
he healthy normal subgroup (n  703) and stage A/B HF
ubgroup (n 1,288) are shown in Table 1. Healthy normal
ubjects were younger and had lower BMI levels than stage
Figure 2 Cumulative Survival and Event-Free Survival in the He
Kaplan-Meier curves for unadjusted cumulative incidence in the healthy normal su
(D) myocardial infarction according to plasma N-terminal pro–B-type natriuretic pep
and below it (thin line). Follow-up results are truncated after 10 years. Age- and s
80th percentile value was 196 pg/ml for women and 125 pg/ml for men./B HF subjects. Systolic and diastolic blood pressure,
reatinine, left atrial volume, and left ventricular mass were
ignificantly lower in the healthy normal subgroup com-
ared with the stage A/B HF subgroup. Interestingly, total
holesterol and high-density lipoprotein were higher in
ealthy normal subjects as compared with stage A/B HF
ubjects. The prevalence of the traditional clinical risk
actors and structural/functional cardiac abnormalities that
efine the stage A/B HF subgroup are shown in Table 2.
mportantly, the healthy normal subgroup by definition was
ree of traditional clinical risk factors and structural/
unctional changes of the heart. Age- and sex-specific 80th
ercentile values for plasma NT-proBNP in the total study
ample (n 1,991 [excluding stage C/D HF]) are shown in
igure 1. Female sex and increasing age were both associ-
ted with higher 80th percentile values, but all age- and
ex-specific 80th percentile values were below the HF
iagnosis threshold (23–25). There was a greater prevalence
f subjects with NT-proBNP value above the 80th percen-
Normal Subgroup
(n  703) for (A) death, (B) heart failure, (C) cerebrovascular accident, and
T-proBNP) values above the age- and sex-specific 80th percentile (thick line)
cific 80th percentile NT-proBNP values are shown in Figure 1. The average overallalthy
bgroup
tide (N
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NT-proBNP in Healthy Normal Subjects May 11, 2010:2140–7ile in the stage A/B HF subgroup (24.7%) compared with
he healthy normal subgroup (12.8%). The average overall
T-proBNP 80th percentile value was 196 pg/ml and 125
g/ml for women and men, respectively.
ortality and cardiovascular morbidity. HEALTHY NORMAL
UBGROUP. In the healthy normal subgroup, a cohort of
03 subjects free of traditional clinical risk factors and
tructural/functional cardiac abnormalities, there were 19
ll-cause deaths, 13 HF events, 38 CVA, and 14 myocardial
nfarctions. Kaplan-Meier plots for the unadjusted inci-
ence of death, HF, CVA, and myocardial infarction in the
ealthy normal subgroup according to plasma NT-proBNP
evels above and below the age- and sex-adjusted 80th
ercentile are shown in Figure 2. In the healthy normal
ubgroup, there was no increased risk of death, HF, CVA,
r myocardial infarction among subjects with plasma NT-
roBNP levels greater than the age- and sex-specific 80th
ercentile. Age-, sex-, and BMI-adjusted hazard ratios for
eath, HF, CVA, and myocardial infarction according to
aseline plasma NT-proBNP (greater than the age- and
ex-adjusted 80th percentile as well as a continuous variable)
re presented in Table 3. Because of the relatively small
umber of end points in the healthy normal group, we
valuated a combined end point including death, HF, CVA,
nd myocardial infarction. There were 72 combined events
n the healthy normal cohort, and there was no increase in
he cumulative incidence of the combined end point among
ubjects with NT-proBNP values above the age- and
ex-specific 80th percentile or when NT-proBNP was
nalyzed as a continuous variable (Table 3).
ortality and cardiovascular morbidity. STAGE A/B HF
UBGROUP. In contrast to the healthy normal subgroup,
here were 170 all-cause deaths, 156 HF events, 236 CVA,
nd 133 myocardial infarctions among the 1,288 partici-
ants in the stage A/B HF subgroup. Figure 3 shows
aplan-Meier plots for the unadjusted cumulative incidence
Mortality and Cardiovascular Morbidity in the H(n  703) During 10 Years of F llow-Up AccordTable 3 Mortality and Cardi vascular Morbi(n  703) During 10 Years of Follo
Outcome (No. of Events)
HR (95% CI) per 1 S
Increase in Log Varia
Death (19)
Unadjusted model 1.52 (0.88–2.62)
Age-, sex-, BMI-adjusted 0.95 (0.47–1.92)
Heart failure (13)
Unadjusted model 1.21 (0.63–2.35)
Age-, sex-, BMI-adjusted 1.36 (0.61–3.01)
Myocardial infarction (14)
Unadjusted model 0.71 (0.40–1.28)
Age-, sex-, BMI-adjusted 0.72 (0.33–1.59)
Cerebrovascular accident (38)
Unadjusted model 1.06 (0.74–1.52)
Age-, sex-, BMI-adjusted 0.79 (0.49–1.26)
Combined end point (72)
Unadjusted model 1.04 (0.79–1.37)
Age-, sex-, BMI-adjusted 0.93 (0.65–1.33)CI  confidence interval; HR  hazard ratio; NT-proBNP  N-terminal pro–B-f death, HF, CVA, and myocardial infarction in the stage
/B HF subgroup according to plasma NT-proBNP levels
bove and below the age- and sex-specific 80th percentile.
here was a significantly higher cumulative incidence for
ach outcome among subjects with plasma NT-proBNP
evels above the age- and sex-specific 80th percentile. Age-,
ex-, and BMI-adjusted as well as multivariable analysis
azard ratios for death, HF, CVA, and myocardial infarc-
ion according to baseline plasma NT-proBNP (greater
han the age- and sex-adjusted 80th percentile as well as a
ontinuous variable) are presented in Table 4. In the stage
/B HF subgroup, plasma NT-proBNP was indepen-
ently associated with increased death, HF, CVA, and
yocardial infarction even after adjustment for tradi-
ional clinical risk factors and structural/functional car-
iac abnormalities (Table 4).
The IDI was estimated to assess the discriminative value
f NT-proBNP beyond known traditional clinical risk
actors for each outcome. When adding NT-proBNP to a
odel including age, sex, BMI, total cholesterol, serum
reatinine, diabetes mellitus, hypertension, and CAD, the
ncrease in IDI ( SE) was 1.23  0.45%, 1.41  0.59%,
.65  0.41%, and 0.56  0.25% for death, HF, CVA, and
yocardial infarction, respectively. The improvement was
ignificant (p  0.05) for all outcomes except myocardial
nfarction (p 0.11). Respective c-statistics for models with
he above traditional clinical risk factors alone and with
linical risk factors plus NT-proBNP were 0.79 and 0.80 for
eath, 0.76 and 0.78 for HF, 0.71 and 0.72 for CVA, and
.76 and 0.77 for myocardial infarction.
iscussion
he current study is the first to analyze the prognostic
ignificance of NT-proBNP in a large, entirely normal
ample free of traditional clinical cardiovascular risk factors
y Normal SubgroupBaseline NT-proBNPn the Healthy Normal Subgroup
According to Baseline NT-proBNP
p Value
HR (95% CI) for Values
Above 80th Percentile p Value
0.132 0.72 (0.17–3.09) 0.655
0.881 1.06 (0.24–4.74) 0.938
0.564 1.19 (0.26–5.38) 0.819
0.452 1.69 (0.36–7.96) 0.507
0.255 0.45 (0.06–3.39) 0.435
0.421 0.66 (0.08–5.23) 0.697
0.738 0.61 (0.22–1.73) 0.356
0.320 1.06 (0.37–3.05) 0.915
0.765 0.76 (0.36–1.57) 0.454
0.688 1.14 (0.53–2.42) 0.736ealthing todity i
w-Up
D
bletype natriuretic peptide; other abbreviations as in Table 1.
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May 11, 2010:2140–7 NT-proBNP in Healthy Normal Subjectsnd structural/functional echocardiographic abnormalities
healthy normal subjects). In this subgroup, which repre-
ented 34% of the 2,042 subjects in a community-based
ample and 703 of 1,991 subjects in the current analysis, the
rognostic significance of plasma NT-proBNP for mortal-
ty, HF, CVA, and myocardial infarction was absent,
uggesting that NT-proBNP lacks prognostic significance
n healthy normal subjects. Similar to previous reports,
T-proBNP had significant prognostic value for mortality,
F, CVA, and myocardial infarction among subjects with
tage A/B HF. It should be noted that the NT-proBNP
alues associated with increased risk were well below those
een with HF (23–25), and that the prognostic value
emained significant even after adjustment for traditional
linical cardiovascular risk factors and structural/functional
chocardiographic abnormalities, including diastolic dys-
unction.
The important observation from our investigations that
Figure 3 Cumulative and Event-Free Survival in the Stage A/B
Kaplan-Meier curves for unadjusted cumulative incidence in the stage A/B heart fa
dent, and (D) myocardial infarction according to plasma N-terminal pro–B-type natr
(thick line) and below it (thin line). Follow-up results are truncated after 10 years
average overall 80th percentile value was 196 pg/ml for women and 125 pg/ml foT-proBNP lacks prognostic value in the healthy normal aohort has clear implications on the use of NT-proBNP as
biomarker to identify subjects at increased risk for mor-
ality and cardiovascular morbidity. First, an elevated plasma
T-proBNP alone does not appear sufficient to predict
ubjects at increased risk. Detailed history and echocardio-
raphic examination are also necessary, and only in the
resence of traditional risk factors or echocardiographic
bnormalities (i.e., stage A/B HF) does NT-proBNP have
rognostic value. Again, this is underscored by our obser-
ation that the healthy normal subgroup had subjects with
lasma NT-proBNP values above the 80th percentile, but
uch values were of no prognostic significance. Second,
hese findings will have important implications as future
roof-of-concept and interventional trials are planned to
dentify at-risk subjects based on elevated NT-proBNP
evels. Only subjects with at-risk NT-proBNP values and
ither risk factors and/or structural or functional changes of
he heart (stage A/B HF) should be candidates for more
t Failure Subgroup
ubgroup (n  1,228) for (A) death, (B) heart failure, (C) cerebrovascular acci-
peptide (NT-proBNP) values above the age- and sex-specific 80th percentile
and sex-specific 80th percentile NT-proBNP values are shown in Figure 1. The
.Hear
ilure s
iuretic
. Age-
r menggressive risk management. Importantly, we advocate stud-
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NT-proBNP in Healthy Normal Subjects May 11, 2010:2140–7es be undertaken to determine if reduction of NT-proBNP
n stage A/B HF by more aggressive risk management
mproves outcomes and survival.
The mechanism for the absence of prognostic value of
T-proBNP (both above the age- and sex-adjusted 80th
ercentile and as a continuous variable) in healthy normal
ubjects remains to be elucidated. One explanation would be
oo few individual events in the healthy normal subgroup to
redict mortality and cardiovascular morbidity based on
lasma NT-proBNP. Indeed, for the combined end point of
eath, HF, CVA, and myocardial infarction, for which
here were 72 total events in the healthy normal subgroup,
he current study was powered to detect an HR of 2.29.
hile underpowered because of the low event rate to detect
moderate association (hazard ratios of 1.5 to 2.0) of
T-proBNP with adverse outcomes in the healthy normal
ubgroup, the absolute risk is so low that it is difficult to
ustify the widespread use of NT-proBNP in clinically
ormal subjects. It is also possible that a mild elevation in
NP is cardioprotective in the absence of stage A/B HF.
nother potential explanation is that subjects in the healthy
ormal subgroup who have elevated NT-proBNP levels
ay have a greater frequency of a recently reported BNP
ene (NPPB) single-nucleotide polymorphism (rs198389),
hich results in greater circulating levels of BNP in the
bsence of cardiovascular disease (26,27). Although these
ypotheses require further investigation, our findings sug-
Mortality and Cardiovascular Morbidity in the(n  1,228) During 10 Years of Follow-Up AccTable 4 Mo tal ty and Cardi vascular Mor(n  1,228) During 10 Years of F
Outcome (No. of Events)
HR (95% CI) per 1
Increase in Log Vari
Death (170)
Unadjusted model 2.65 (2.23–3.14)
Age-, sex-, BMI-adjusted 1.76 (1.45–2.13)
Multivariable model 1* 1.75 (1.43–2.14)
Multivariable model 2† 1.55 (1.23–1.96)
Heart failure (156)
Unadjusted model 1.75 (1.52–2.01)
Age-, sex-, BMI-adjusted 1.38 (1.18–1.62)
Multivariable model 1* 1.28 (1.09–1.52)
Multivariable model 2† 1.26 (1.05–1.51)
Myocardial infarction (133)
Unadjusted model 2.77 (2.29–3.35)
Age-, sex-, BMI-adjusted 2.30 (1.87–2.84)
Multivariable model 1* 2.16 (1.72–2.70)
Multivariable model 2† 1.63 (1.27–2.09)
Cerebrovascular accident (236)
Unadjusted model 1.68 (1.39–2.02)
Age-, sex-, BMI-adjusted 1.61 (1.31–1.99)
Multivariable model 1* 1.36 (1.07–1.71)
Multivariable model 2† 1.33 (1.03–1.73)
*Adjustment for age, sex, body mass index (BMI), total cholesterol, s
artery disease. †Adjustment for variables in model 1 in addition to pre
left ventricular hypertrophy, left atrial enlargement, and wall motion a
Abbreviations as in Table 3.est that in a large, well-characterized community-based aohort, NT-proBNP lacks prognostic value in healthy
ormal subjects.
A strength of the current investigation was the median
ollow-up of almost 9 years’ duration and in-depth docu-
entation of mortality and cardiovascular events. The
eminal study of Wang et al. (5) documented the utility of
trial natriuretic peptide and BNP in predicting adverse
ardiovascular outcomes in the general community (healthy
ormal and stage A/B HF combined) over a 5.2-year period
f follow-up. The important Heart and Soul study of
atients with CAD and without HF reported the prognostic
ignificance of NT-proBNP over 3.5 years of follow-up
28,29). When all 3 studies are taken together, they rein-
orce the utility of the native cardiac natriuretic peptides as
iomarkers for cardiovascular disease in the general popu-
ation without HF. However, the current study would again
tate that NT-proBNP is not prognostic for mortality or
ardiovascular morbidity in healthy normal subjects.
onclusions
e report the first large community-based sample study of
ealthy normal subjects and stage A/B HF subjects to
etermine the prognostic value of NT-proBNP in predict-
ng mortality and cardiovascular morbidity over a median
.9 years of follow-up. Importantly, the prognostic value of
T-proBNP in healthy normal subjects as verified by
n-depth clinical and echocardiographic examination was
e A/B Heart Failure Subgroupg to Baseline NT-proBNPin the St ge A/B Heart Failure Subgroup
-Up According to Baseline NT-proBNP
p Value
HR (95% CI) for Values
Above 80th Percentile p Value
0.001 1.70 (1.25–2.33) 0.001
0.001 2.01 (1.47–2.75) 0.001
0.001 2.02 (1.45–2.81) 0.001
0.001 1.60 (1.10–2.32) 0.014
0.001 1.60 (1.22–2.09) 0.001
0.001 1.77 (1.35–2.32) 0.001
0.004 1.56 (1.18–2.06) 0.002
0.015 1.51 (1.12–2.03) 0.007
0.001 2.49 (1.82–3.41) 0.001
0.001 3.00 (2.18–4.12) 0.001
0.001 2.63 (1.87–3.68) 0.001
0.001 1.74 (1.20–2.53) 0.004
0.001 2.22 (1.58–3.14) 0.001
0.001 2.49 (1.76–3.52) 0.001
0.011 2.03 (1.41–2.91) 0.001
0.029 2.05 (1.39–3.03) 0.001
reatinine, presence of diabetes mellitus, hypertension, and coronary
f ejection fraction 50%, diastolic dysfunction, valvular dysfunction,
alities.Stagordinbidity
ollow
SD
able
erum c
sence obsent. Thus, our studies do not support the use of NT-
p
s
R
M
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
K
2147JACC Vol. 55, No. 19, 2010 McKie et al.
May 11, 2010:2140–7 NT-proBNP in Healthy Normal SubjectsroBNP as a cardiovascular biomarker in healthy normal
ubjects.
eprint requests and correspondence: Dr. Paul M. McKie,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: mckie.paul@mayo.edu.
EFERENCES
1. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic
peptide and clinical judgment in emergency diagnosis of heart failure:
analysis from Breathing Not Properly (BNP) multinational study.
Circulation 2002;106:416–22.
2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med 2002;347:161–7.
3. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Steven-
son LW, Shekelle PG. Cost-effectiveness of screening with B-type
natriuretic peptide to identify patients with reduced left ventricular
ejection fraction. J Am Coll Cardiol 2004;43:1019–26.
4. McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal
pro-B-type natriuretic peptide and B-type natriuretic peptide: biomar-
kers for mortality in a large community-based cohort free of heart
failure. Hypertension 2006;47:874–80.
5. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels
and the risk of cardiovascular events and death. N Engl J Med
2004;350:655–63.
6. Rosenberg J, Schou M, Gustafsson F, Badskjaer J, Hildebrandt P.
Prognostic threshold levels of NT-proBNP testing in primary care.
Eur Heart J 2009;30:66–73.
7. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hilde-
brandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein,
and urinary albumin levels as predictors of mortality and cardiovascular
events in older adults. JAMA 2005;293:1609–16.
8. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update
incorporated into the ACC/AHA 2005 guidelines for the diagnosis
and management of heart failure in adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1–90.
9. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and
prognostic significance of heart failure stages: application of the
American College of Cardiology/American Heart Association heart
failure staging criteria in the community. Circulation 2007;115:
1563–70.
0. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart
failure in the community: a study of all incident cases in Olmsted
County, Minnesota, in 1991. Circulation 1998;98:2282–9.
1. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Bailey KR,
Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction
in the community: appreciating the scope of the heart failure epidemic.
JAMA 2003;289:194–202.
2. Jacobsen SJ, Mahoney DW, Redfield MM, Bailey KR, Burnett JC Jr.,
Rodeheffer RJ. Participation bias in a population-based echocardiog-
raphy study. Ann Epidemiol 2004;14:579–84.
3. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-
terminal pro-B-type natriuretic peptide and B-type natriuretic peptide yin the general community: determinants and detection of left ventric-
ular dysfunction. J Am Coll Cardiol 2006;47:345–53.
4. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle
in health and disease: Doppler echocardiography is the clinician’s
Rosetta Stone. J Am Coll Cardiol 1997;30:8–18.
5. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic
assessment of left ventricular hypertrophy: comparison to necropsy
findings. Am J Cardiol 1986;57:450–8.
6. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB,
Castelli WP. Echocardiographic criteria for left ventricular hypertro-
phy: the Framingham Heart Study. Am J Cardiol 1987;59:956–60.
7. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR,
Redfield MM. Left atrial volume as an index of left atrial size: a
population-based study. J Am Coll Cardiol 2003;41:1036–43.
8. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R.
Analytical performance of the N terminal pro B type natriuretic
peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers.
Eur J Heart Fail 2004;6:365–8.
9. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR,
Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact
of age and gender. J Am Coll Cardiol 2002;40:976–82.
0. Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med
2008;27:157–72, discussion 207–12.
1. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and
mortality among patients on the liver-transplant waiting list. N Engl
J Med 2008;359:1018–26.
2. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination
in survival analysis: model specific population value and confidence
interval estimation. Stat Med 2004;23:2109–23.
3. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP
testing for diagnosis and short-term prognosis in acute destabilized
heart failure: an international pooled analysis of 1256 patients. The
International Collaborative of NT-proBNP Study. Eur Heart J 2006;
27:330–7.
4. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the
diagnosis and management of heart failure. Can Med Assoc J
2006;175:611–7.
5. Clerico A, Prontera C, Emdin M, et al. Analytical performance and
diagnostic accuracy of immunometric assays for the measurement of
plasma B-type natriuretic peptide (BNP) and N-terminal proBNP.
Clin Chem 2005;51:445–7.
6. Meirhaeghe A, Sandhu MS, McCarthy MI, et al. Association between
the T-381C polymorphism of the brain natriuretic peptide gene and
risk of type 2 diabetes in human populations. Hum Mol Genet
2007;16:1343–50.
7. Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, et al. B-type
natriuretic peptide single nucleotide polymorphism rs198389 impacts
test characteristics of common assays (abstr). Circulation 2009;120
Suppl:S777.
8. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA.
Biomarkers to predict recurrent cardiovascular disease: the Heart and
Soul Study. Am J Med 2008;121:50–7.
9. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley
MA. N-terminal fragment of the prohormone brain-type natriuretic
peptide (NT-proBNP), cardiovascular events, and mortality in patients
with stable coronary heart disease. JAMA 2007;297:169–76.
ey Words: natriuretic peptide y predictive y mortality y heart failure
myocardial infarction y cerebrovascular accident.
